Optimized approaches for quantification of drug transporters in tissues and cells by MRM proteomics
about
Recent advances in understanding hepatic drug transportDatabase of Optimized Proteomic Quantitative Methods for Human Drug Disposition-Related Proteins for Applications in Physiologically Based Pharmacokinetic Modeling.Role of (drug) transporters in imaging in health and disease.Predictors of Variation in CYP2A6 mRNA, Protein, and Enzyme Activity in a Human Liver Bank: Influence of Genetic and Nongenetic Factors.LC-MS/MS quantification of sulfotransferases is better than conventional immunogenic methods in determining human liver SULT activities: implication in precision medicine.The role of quantitative ADME proteomics to support construction of physiologically based pharmacokinetic models for use in small molecule drug development.The CYP2C19 Intron 2 Branch Point SNP is the Ancestral Polymorphism Contributing to the Poor Metabolizer Phenotype in Livers with CYP2C19*35 and CYP2C19*2 Alleles.Developmental Regulation of Drug-Processing Genes in Livers of Germ-Free MiceAtenolol Renal Secretion Is Mediated by Human Organic Cation Transporter 2 and Multidrug and Toxin Extrusion Proteins.Interindividual variability of CYP2C19-catalyzed drug metabolism due to differences in gene diplotypes and cytochrome P450 oxidoreductase contentAbundance of Hepatic Transporters in Caucasians: A Meta-Analysis.The Promises of Quantitative Proteomics in Precision Medicine3D Proximal Tubule Tissues Recapitulate Key Aspects of Renal Physiology to Enable Nephrotoxicity Testing.Ontogeny of Hepatic Drug Transporters and Relevance to Drugs Used in Pediatrics.Transporter Expression in Liver Tissue from Subjects with Alcoholic or Hepatitis C Cirrhosis Quantified by Targeted Quantitative ProteomicsAge-Dependent Absolute Abundance of Hepatic Carboxylesterases (CES1 and CES2) by LC-MS/MS Proteomics: Application to PBPK Modeling of Oseltamivir In Vivo Pharmacokinetics in Infants.Trafficking and other regulatory mechanisms for organic anion transporting polypeptides and organic anion transporters that modulate cellular drug and xenobiotic influx and that are dysregulated in disease.Harnessing Solute Carrier Transporters for Precision Oncology.Abundance of Drug Transporters in the Human Kidney Cortex as Quantified by Quantitative Targeted Proteomics.Choice of LC-MS methods for the absolute quantification of drug-metabolizing enzymes and transporters in human tissue: a comparative cost analysis.Transport vs. Metabolism: What Determines the Pharmacokinetics and Pharmacodynamics of Drugs? Insights From the Extended Clearance Model.Transporter expression in non-cancerous and cancerous liver tissue from donors with hepatocellular carcinoma and chronic hepatitis C infection quantified by LC-MS/MS proteomics.Critical Issues and Optimized Practices in Quantification of Protein Abundance Level to Determine Interindividual Variability in DMET Proteins by LC-MS/MS Proteomics.The concept of fraction of drug transported (ft ) with special emphasis on BBB efflux of CNS and antiretroviral drugs.Polymorphic Human Sulfotransferase 2A1 Mediates the Formation of 25-Hydroxyvitamin D3-3-O-sulfate, A Major Circulating Vitamin D Metabolite in Humans.PBDEs Altered Gut Microbiome and Bile Acid Homeostasis in Male C57BL/6 Mice
P2860
Q28077066-868ACB7E-A8B8-4AF7-AAA7-0E8AA37D27C4Q30490654-0D27E7B1-0C9D-4B48-8581-329EDBE3F79DQ30854787-607119BE-A67F-4914-9C0D-2F292B5A32BBQ33458739-4C170359-F38F-47DF-954E-238E6F3BC9A0Q33818825-6FB17949-4EDC-43FD-AAE7-EC7C6BB928A1Q35560052-B7ECB1EC-0934-4C4B-8C0E-4FEC1888017BQ35897778-6BB9B854-6B79-458D-8343-214A63282090Q36027794-3EB8C1D8-7FE9-4673-9320-E349718E47F9Q36316489-357EE9DA-5184-4A5C-86F1-E1A2863DBD79Q36643041-DCFEC6B4-77C5-41E5-BF4F-AAD3953BF6A6Q37279044-635D86EB-4D03-426E-8773-EDD98F4DBA9BQ37647264-C5DEDBAF-F26D-480B-A827-BF18A1940907Q37685354-E6F3D678-A0B9-4AD9-9EA6-E0F01A9A3E17Q38682009-4A51547C-589B-4443-AAE9-A5BD2F815C92Q38829596-4AC28DED-5D93-45DA-929D-4C940F998753Q39147483-BC42E21C-730A-4F5D-A304-F5ED03FC493CQ39181492-64040E38-2A4A-458A-8D48-5E4F9E299200Q39204754-39B5EB99-84F0-4D88-AE6E-C6B48286ADD7Q39398250-4D40C3A1-AFF8-45AA-8DEA-79F5A5F20A9CQ41461755-33438DF4-4E01-47FA-B40D-095FEA4731AFQ42682232-A7507D96-8046-41AF-A15B-CEC8D847B7ECQ47402203-0DF16188-D37D-4642-A71E-22ADE6499B35Q47917027-DD38D86D-D57F-4C87-90CF-D2CD14539C92Q48335227-ED62275F-E104-4A66-8CD2-5D8596278AA0Q49989942-A33324BF-08BA-45DC-8BE8-D6D27B8C3795Q57112967-B11EDB7F-572C-4DE0-8EDE-C20E5E9A2625
P2860
Optimized approaches for quantification of drug transporters in tissues and cells by MRM proteomics
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Optimized approaches for quant ...... es and cells by MRM proteomics
@ast
Optimized approaches for quant ...... es and cells by MRM proteomics
@en
Optimized approaches for quant ...... es and cells by MRM proteomics
@nl
type
label
Optimized approaches for quant ...... es and cells by MRM proteomics
@ast
Optimized approaches for quant ...... es and cells by MRM proteomics
@en
Optimized approaches for quant ...... es and cells by MRM proteomics
@nl
prefLabel
Optimized approaches for quant ...... es and cells by MRM proteomics
@ast
Optimized approaches for quant ...... es and cells by MRM proteomics
@en
Optimized approaches for quant ...... es and cells by MRM proteomics
@nl
P2860
P3181
P1433
P1476
Optimized approaches for quant ...... es and cells by MRM proteomics
@en
P2093
Bhagwat Prasad
Jashvant D. Unadkat
P2860
P2888
P304
P3181
P356
10.1208/S12248-014-9602-Y
P407
P577
2014-07-01T00:00:00Z
P6179
1041389567